EP2429528A2 - Comprimé à fondre contenant un sel de vardenafil - Google Patents

Comprimé à fondre contenant un sel de vardenafil

Info

Publication number
EP2429528A2
EP2429528A2 EP10721683A EP10721683A EP2429528A2 EP 2429528 A2 EP2429528 A2 EP 2429528A2 EP 10721683 A EP10721683 A EP 10721683A EP 10721683 A EP10721683 A EP 10721683A EP 2429528 A2 EP2429528 A2 EP 2429528A2
Authority
EP
European Patent Office
Prior art keywords
orodispersible
tablet
vardenafil
tablets
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10721683A
Other languages
German (de)
English (en)
Inventor
Ralph Stefan
Sandra Brueck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ratiopharm GmbH
Original Assignee
Ratiopharm GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm GmbH filed Critical Ratiopharm GmbH
Publication of EP2429528A2 publication Critical patent/EP2429528A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Definitions

  • the invention relates to a method of producing orodispersible tablets containing a pharmaceutically acceptable salt of vardenafil comprising the steps of (i) preparing a mixture containing pharmaceutically acceptable vardenafil salt, mucilage, sweetening, flavoring agents, and (U) directly compressing the mixture into orodispersible tablets.
  • the invention likewise relates to tablets obtainable by the process according to the invention.
  • vardenafil The IUPAC name of vardenafil [INN] is 2-ethoxy-5 - [(4-ethyl-1-piperazinyl) sulfonyl] phenyl ⁇ -5-methyl-7-propylimidazo [5, l -f] [l, 2, 4] triazin-4 (3H) -one.
  • the chemical structure of vardenafil is shown in formula (1) below:
  • Vardenafil is a potent selective inhibitor of cGMP-specific phosphodiesterase type 5 (PDE-5), which is responsible for the reduction of cGMP in the corpus cavernosum.
  • Vardenafil is sold under the trade name Levitra ® for the treatment of erectile dysfunction. The production of vardenafil has been described in WO 99/24433.
  • WO 2007/02125 describes sublingual tablets containing PDE-5 inhibitors, such as vardenafil or vardenafil salts.
  • PDE-5 inhibitors such as vardenafil or vardenafil salts.
  • the tablets prepared in the examples have a bitter taste which is unacceptable to the patient.
  • an object of the present invention to provide an oral dosage form with a short disintegration time in the mouth and a process for its preparation.
  • the oral dosage form should be producible with variable active ingredient content.
  • the total weight of the tablets should be low.
  • the use of the free vardenafil base should be avoided.
  • an oral dosage form which is pleasant to the patient, e.g. a dosage form that achieves acceptable taste in the patient (i.e., the patient should not experience a bitter taste). The patient should not feel the dosage form unpleasantly in the mouth.
  • the acceptable taste should also be made possible with a sugar-free formulation.
  • the abovementioned objects are to be achieved in a high space-time yield by means of a technically simple (and thus cost-effective) process.
  • the objects could be achieved by producing a orodispersible tablet containing a pharmaceutically acceptable salt of vardenafil, a mucilage and other pharmaceutical excipients by direct compression.
  • the invention therefore relates to a process for the preparation of orodispersible tablets containing a pharmaceutically acceptable salt of vardenafil comprising the steps
  • the invention further relates to tablets obtainable by the process according to the invention.
  • the invention relates to the use of a film which has a water vapor permeability of less than 0.50 g / m 2 d, for packaging a fused tablet containing a medicament for the treatment of erectile dysfunction, in particular for packaging the fused tablet according to the invention.
  • the present invention relates to a fused tablet.
  • the term "orodispersible tablet” is understood to mean an orodispersible tablet as defined in the European Pharmacopoeia, 6th edition, Grundwerk 2008.
  • an orodispersible tablet is an oral tablet disintegrating in the oral cavity.
  • the orodispersible tablet is an uncoated tablet, ie the tablet is uncoated or unfilmed.
  • orodispersible tablets must disintegrate within 3 minutes.
  • the orodispersible tablets according to the invention have a disintegration time of less than 60 seconds, more preferably less than 30 seconds, in particular of less than 20 seconds in the mouth.
  • the disintegration time is determined in accordance with Ph. Eur. 6th edition of Chapter 2.9.1 Test A. If the average disintegration time is referred to in this application, this is to be understood as the average of the disintegration time determination of 10 tablets.
  • the orodispersible tablets according to the invention usually have a total weight of less than 750 mg, more preferably less than 500 mg, in particular less than 300 mg. Usually, the orodispersible tablets according to the invention have a weight of more than 50 mg, preferably 100 mg or more, in particular more than 150 mg.
  • the weight ratio of active ingredient to excipients in the melt tablets according to the invention is usually 4: 1 to 1: 5, preferably from 2: 1 to 1: 3, in particular 1: 1 to 1: 2.
  • orodispersible tablets according to the invention are therefore clearly distinguishable from so-called “chewable tablets", since these usually have a higher weight (about 1.5 to 3 g) and a longer disintegration time.
  • the orodispersible tablets according to the invention usually have a hardness of from 25 to 80 N, preferably from 35 to 70 N, more preferably from 40 to 65 N, in particular from 45 to 60 N, on.
  • the hardness is usually determined according to Ph. Eur., 6th edition, chapter 2.9.8. If reference is made in this application to the average hardness, this is to be understood as the mean value from the hardness determination of 10 tablets.
  • the resulting tablets preferably have a friability of less than 5%, particularly preferably less than 3%, in particular less than 1%.
  • the friability is determined according to Ph. Eur. 6.0, section 2.9.7.
  • the orodispersible tablet according to the invention contains as component (a) a pharmaceutically acceptable vardenafil salt.
  • Examples of pharmaceutically acceptable salts are ammonium salts, hydrochlorides, carbonates, bicarbonates, acetates, lac tates, butyrates, propionates, sulfates, methanesulfonates, citrates, tartrates, nitrates, sulfonates, oxalates and / or succinates.
  • solvates or hydrates of the abovementioned salts can be used as component (a).
  • vardenafil hydrochloride Preferably used is vardenafil hydrochloride.
  • vardenafil hydrochloride is used in the form of the trihydrate.
  • Vardenafil hydrochloride in the form of the trihydrate is preferably prepared according to WO 2008/15181 1 A2.
  • the orodispersible tablets according to the invention usually comprise component (a) in a proportion of from 1 to 60% by weight, preferably from 2 to 25% by weight, in particular from 5 to
  • the orodispersible tablets according to the invention usually contain component (a) in an amount from 2 to 50 mg, more preferably from 5 to 20 mg.
  • the orodispersible tablets according to the invention contain 5 mg, 10 mg or 20 mg of component (a), based on the content of vardenafil base.
  • 11, 85 mg vardenafil hydrochloride trihydrate corresponds to 10 mg vardenafil base.
  • the orodispersible tablets according to the invention preferably comprise one (or more) mucilages as component (b).
  • mucilages are usually understood to mean substances which are e.g. reduce the contact of drugs with the papillae by increasing the viscosity or by wrapping. This usually achieves a reduction in the intensity of the taste sensation.
  • substances are selected which are in the form of a 2% by weight solution or mixture in distilled water to a viscosity of more than 2 mPa / s, preferably more than 4 mPa / s, in particular more as 6 mPa / s, measured at 25 0 C, determined according to Ph. Eur., 6th edition, chapter 2.2.10.
  • mucilages (b) natural substances or synthetic substances (e.g., swellable polymers) can be used.
  • Examples of (natural) mucilages are agar, alginic acid, alginate, chicle, carrageenan, dammar, marshmallow extracts, gellan (E 418), guar gum (E 412), gum arabic (E 414), maple gum gum, spruce sap , Locust bean gum E 410), karaya (E 416), konjac flour (E 425), extracted from the konjac root, tara gum (E 417), tragacanth (E 413), xanthan gum (E 415), preferably produced by bacterial fermentation, guar gum, starch, in particular gelatinized maize starch (eg available as starch 1500 ®) and / or lecithin.
  • guar gum in particular gelatinized maize starch (eg available as starch 1500 ®) and / or lecithin.
  • synthetic mucilage may also be used.
  • polymeric synthetic gums are used.
  • Polymer here is to be understood as meaning a substance having two or more repeating monomer units.
  • the polymeric mucilages optionally have hydrophilic groups.
  • suitable hydrophilic groups are hydroxy, amino, ester, carboxylic acid or carboxylate.
  • the polymers used as slurries (b) preferably have ester groups or ester and amino groups.
  • the polymeric gums (b) preferably have a weight average molecular weight of from 1000 to 10 8 g / mol, more preferably from 10,000 to 10 6 g / mol.
  • the polymeric gums (b) are preferably crosslinked.
  • the polymer (b) in this case preferably has a crosslinking degree of from 0.01 to 10%, especially from 0.1 to 5%.
  • (Degree of crosslinking number of carbon atoms that are more than one chain / total number of carbon atoms in the polymer chain).
  • a "water-swellable polymer” is used as the gum (b).
  • swelling it is meant here that the polymer is capable of accumulating or storing water molecules on contact with water, preferably the weight ratio of polymer dehydrated to polymer swollen at 1: 1, 1 to 1: 100, more preferably 1: 2 to 1: 20.
  • polyvinylpyrrolidone e.g., polyvinylpyrrolidone, , crosslinked polyvinylpyrrolidone (for example available as Kollidon ® CL).
  • a polymer having a pH-dependent solubility is used as the gum (b).
  • the polymer (b) is not water-soluble in an aqueous solution having a pH of greater than 4.5, 5.0 or 5.5.
  • the polymer (b) is water-soluble in an aqueous solution having a pH of less than 4.5, 5.0 or 5.5.
  • “Non-water-soluble” here means a solubility of 10 mg / 1 or less (determined according to column elution method according to EU Directive RL67-548-EEC, Annex V, Chapter A6).
  • Carrageenan especially according to Ph.Eur.
  • an acrylic polymer is particularly preferably used as component (b).
  • Preferred acrylic polymers are e.g. Polyacrylates, polymethacrylates and their derivatives and mixtures or copolymers thereof.
  • the polyacrylates used preferably have the aforementioned parameters (e.g., Mw, solubility, etc.).
  • the acrylic polymer (b) is a polymer composed of structures represented by the general formulas (2) and (3).
  • R 1 represents a hydrogen atom or an alkyl group, preferably a hydrogen atom or a
  • Methyl radical in particular a methyl radical
  • R 2 is a hydrogen atom or an alkyl radical, preferably a hydrogen atom or a C 1 to C 4 alkyl radical, in particular a methyl radical, ethyl radical or butyl;
  • R 3 is a hydrogen atom or an alkyl radical, preferably a hydrogen atom or a methyl radical
  • R 4 is an organic radical, preferably a carboxylic acid group or a derivative thereof, more preferably a group of the formula -COOH, -COOR 5 ,
  • R 5 is an alkyl radical or a substituted alkyl radical, preferably methyl, ethyl, propyl or
  • the acrylic polymer (b) contains structures according to the formulas (2) and (3) usually in molar ratios of 1:40 to 40: 1.
  • the ratio of structures according to formula (2) to structures according to formula (3) 2 is preferably: 1 to 1: 1, in particular 1: 1. If R 4 is -COO-CH 2 -CH 2 -N (CH 3 J 3 + Cr, the ratio of structures of the formula (2) to structures of the formula (3) is preferred 20: 1 to 40: 1.
  • a suitable polymer has in particular a weight average molecular weight of from 50,000 to 250,000 g / mol, more preferably from 120,000 to 180,000 g / mol, up.
  • the radical R 2 represents both a methyl and a butyl group, wherein the ratio of methyl to butyl groups is preferably 1: 1.
  • component (b) is usually used in an amount of 0.1 to 30% by weight, preferably 1 to 0 to 25% by weight, more preferably 1 to 5 to 20% by weight. even more preferably from 2.0 to 15% by weight, more preferably from 2.5 to 10% by weight, especially from 3.0 to 8% by weight, based on the total weight of the tablet.
  • the orodispersible tablet according to the invention contains a plurality of different mucilages, for example the tablet according to the invention may contain 2 or 3 different mucilages.
  • the orodispersible tablets according to the invention contain as component (c) one or more sweeteners.
  • Sweeteners are generally referred to as substances which usually produce a sweet taste impression on the patient when taken.
  • lactose (0.27-0.3), glycerol (0.5-0.8), D-glucose (0.5-0.6), maltose (0.6), galactose (0.6) , Invert sugar (0.8-0.9), cane sugar (1, 0), xylitol (1, 0), D-fructose (1, 0-1, 5), sodium cyclamate (30), D-tryptophan (35) , chloroform (40), glycyrrhizin (50), acesulfame (130), aspartame (180-200), dulcin (200), suosan ® (350), saccharin (sodium salt) (400-500), saccharin (ammonium salt) (600 ), 1-bromo-5-nitroaniline (700), naringinedehydrochalcone (1000-1500), thaumatin, monellin (peptides) (3000), P-4000, n-propoxy-2-amino-4-nitrobenzene (4000),
  • component (c) is usually used in an amount of from 0.01 to 10% by weight, more preferably from 0.1 to 5% by weight, in particular from 0.5 to 2% by weight, based on the total weight of the tablet used.
  • the orodispersible tablet according to the invention contains a plurality of different sweeteners, more preferably the tablet according to the invention contains 2, 3 or 4 different sweeteners.
  • component (c) (C-1) contains an immediate sweetener and (c-2) a sweet sweetener.
  • the components (c-1) and (c-2) may usually be used in a weight ratio of 5: 1 to 1: 5, preferably 3: 1 to 1: 3.
  • Examples of an instant sweetener (c-1) are saccharin sodium salt, saccharin ammonium salt, sucralose, neotame, alitame, aspartame, cyclamate, thaumatin and / or acesulfame.
  • sweeteners with delayed sweetness are glycyrrhizin or derivatives thereof, especially glycyrrhizin in the form of the mono-ammonium salt, thaumatin and neohesperidin DC.
  • the orodispersible tablets according to the invention contain as component (d) one or more flavoring agents.
  • flavoring agent is to be understood as defined in Council Directive 88/388 / EEC "flavoring substances" of 22 June 1988.
  • Flavoring agents (d) can be obtained as follows:
  • a flavoring agent may in this case consist of one or preferably of several chemical compounds.
  • peppermint flavor may contain a collective of more than 10 chemical compounds.
  • component (d) is usually contained in an amount of 0.001 to 5% by weight, more preferably 0.1 to 4% by weight, especially 0.2 to 2% by weight, based on the total weight of the tablet used. It should be noted in these quantities that component (d) is optionally used in a "supported form". In this case, the above statement refers to flavoring agents including carriers.
  • the orodispersible tablet according to the invention contains several different flavoring agents (ie several different aroma directions), more preferably the tablet according to the invention contains 2, 3 or 4 different flavoring agents.
  • Preferred combinations of flavoring agents are e.g. Aroma Peppermint with Aroma Menthol, Aroma Peppermint Aroma Lemon, Aroma Peppermint Aroma Menthol and Aroma Lemon, Aroma Garden Mint Aroma Lemon, Aroma Garden Mint Aroma Menthol, Aroma Garden Mint Aroma Lemon and Aroma Menthol, Aroma Grapefruit Aroma Peppermint, Aroma Grapefruit with aroma menthol and aroma peppermint, aroma grapefruit with aroma garden mint, aroma grapefruit with aroma garden mint and aroma menthol.
  • the orodispersible tablet according to the invention further contains one or more mouthfeel improving agents (as component (e)).
  • mouthfeel describes the physical and chemical interactions of a substance or a substance mixture (in the present case, in particular, the orodispersible tablet according to the invention) in the mouth. This includes the impressions from the first palate contact on the chewing to the swallowing and the aftertaste.
  • the mouthfeel can be described by the following criteria, for example:
  • o Lining of the mouth type and extent of coating of teeth and mucous membrane of the oral cavity. Of interest is usually the lining after chewing or disintegration of the sample, so just before swallowing; o density: density of the cut surface in terms of a density of the package, after a sample has been completely severed with the molars; o elasticity: ability of the sample to return to its original shape after the application of force; o hardness: measure of the subjectively perceived force to deform the sample by a defined distance; o Moisture: amount of perceived on the surface of the sample
  • o Uniformity Describes the uniformity of a sample (taste, texture, color, etc.); o Granularity: the degree of granularity felt during the chewing process; o Adhesion: The force needed to remove the material being tested from a specific surface (lips, teeth, palate, etc.); roughness: the degree of felt that the sample leaves on the tongue; Slipperiness: the extent to which the sample slides over the tongue; o Heavy: At the first contact on the tongue felt weight of the sample; o Shredding: The force needed to break up the sample.
  • substances which are water-soluble are selected as component (e). These are preferably water-soluble polymers or sugar alcohols.
  • the water-soluble polymer has a solubility of more than 10 mg / l, more preferably more than 30 mg / l, in particular more than 250 mg / l.
  • hydrophilic polymers are preferably used as the water-soluble component (b). These are polymers which have hydrophilic groups. Examples of suitable hydrophilic groups are hydroxy, alkoxy, acrylate, methacrylate, sulfonate, carboxylate and quaternary ammonium groups.
  • the water-soluble polymer (s) may comprise, for example, the following polymers: starch, in particular pregelatized starch, carboxymethylcellulose (CMC, in particular sodium and calcium salts), crospovidone, polyvinylpyrrolidone (povidone), polyvinyl acetate (PVAC), polyvinyl alcohol (PVA), vinylpyrrolidone-vinyl acetate copolymers (for example Kollidon ® VA64, BASF), polyalkylene glycols such as polypropylene glycol or, preferably, polyethylene glycol, co-block polymers of the polyethylene glycol, in particular co-block polymers of polyethylene glycol and polypropylene glycol (Pluronic ®, BASF), and mixtures of said polymers.
  • starch in particular pregelatized starch, carboxymethylcellulose (CMC, in particular sodium and calcium salts), crospovidone, polyvinylpyrrolidone (povidone), polyvinyl acetate (
  • the water-soluble polymer preferably has a weight-average molecular weight (determined by light scattering method) of 1,000 to 100,000 g / mol, more preferably 4,000 to 70,000 g / mol, especially 5,000 to 50,000 g / mol.
  • the weight-average molecular weight is preferably 2,000 to 10,000 g / mol.
  • Suitable sugar alcohols (e) are mannitol, sorbitol, xylitol, isomalt, glucose, fructose, maltose and mixtures thereof.
  • Component (e) particularly preferably contains one or more compounds from the group consisting of sugar alcohols (in particular mannitol), polyvinyl acetate, Vinylpyrrolidone-vinyl acetate copolymers, polyvinylpyrrolidone and starch (especially pregelatized starch).
  • the component (e) is usually used in an amount of from 0 to 50% by weight, more preferably from 1 to 35% by weight, especially from 5 to 25% by weight, based on the total weight of Tablet.
  • the orodispersible tablet according to the invention contains several different substances for improving the mouthfeel, more preferably the tablet according to the invention contains 2 to 5 different substances for improving the mouthfeel.
  • the orodispersible tablet according to the invention also contains a lubricant (as component (f)).
  • Flow regulators (f) have the task of reducing the interparticle friction (cohesion) between the individual particles as well as the adhesion of these to the wall surfaces of the mold (adhesion) in a tabletting mixture.
  • An example of an additive for improving powder flowability is disperse silica. Preference is given to using silica having a specific surface area of from 50 to 400 m 2 / g, determined by gas adsorption in accordance with Ph. Eur., 6th edition, Sept. 2, 1966. In this connection, it was unexpectedly found that by using silica having a specific surface area of 50 to 400 m 2 / g, the amount of filler can be advantageously reduced.
  • Lubricants can be used as component (f).
  • Lubricants are generally used to reduce sliding friction.
  • the sliding friction is to be reduced, which consists during tabletting on the one hand between the up and down in the die bore moving punches and the die wall and on the other hand between the tablet web and die wall.
  • Suitable lubricants are for example stearic acid, adipic acid, sodium stearyl fumarate represents (eg Pruv ®), sodium stearyl sulfate, sodium lauryl sulfate, magnesium stearate and / or calcium stearate.
  • the component (f) is usually used in an amount of 0 to 5% by weight, more preferably 0 to 1 to 3% by weight, especially 0.3 to 2% by weight on the total weight of the tablet.
  • the fused tablet according to the invention can consist of components (a) to (d) and optionally (e) and (f).
  • the tablet of the invention may contain other conventional pharmaceutical excipients.
  • Examples are disintegrants, fillers and acidulants.
  • disintegrants are generally referred to substances that accelerate the disintegration of a dosage form, in particular a tablet, after being introduced into water.
  • Suitable disintegrants are e.g. organic disintegrants such as microcrystalline cellulose, starch, pregelatinized starch, sodium carboxymethyl starch, sodium carboxymethyl cellulose and crospovidone.
  • microcrystalline cellulose is used as the disintegrant.
  • so-called "super-blasting agents" in particular croscarmellose and crospovidone, be dispensed with.
  • the orodispersible tablets according to the invention contain disintegrants, in particular superdisintegrants (eg croscarmellose and crospovidone), usually in an amount of from 0 to 25% by weight, more preferably from 1 to 15% by weight, in particular from 2 to 10% by weight, based on the total weight of the tablet.
  • disintegrants in particular superdisintegrants (eg croscarmellose and crospovidone)
  • the orodispersible tablets according to the invention contain these in an amount of from 1 to 50% by weight, more preferably from 5 to 35% by weight, in particular from 10 to 25% by weight. Larger amounts of microcrystalline cellulose should be avoided, otherwise the mouthfeel will be adversely affected.
  • Fillers are generally to be understood as meaning substances which serve to form the tablet body in the case of tablets with small amounts of active ingredient (for example less than 30% by weight). That is, fillers produce by "stretching" of the active ingredients sufficient Tablettiermasse. So fillers are usually used to obtain a suitable tablet size.
  • Examples of preferred fillers are lactose, calcium phosphate, sucrose, calcium carbonate, calcium silicate, magnesium carbonate, magnesium oxide, maltodextrin, calcium sulfate, dextrate, dextrin, dextrose, hydrogenated vegetable oil and / or cellulose derivatives.
  • the orodispersible tablets according to the invention usually contain fillers in an amount of from 0 to 30% by weight, more preferably from 1 to 20% by weight, in particular from 2 to 10% by weight, based on the total weight of the tablet.
  • Acid agents are used to achieve an acidic flavor component.
  • acidic agents are citric acid, tartaric acid and salts thereof.
  • the orodispersible tablets according to the invention usually contain acidifying agents in an amount of from 0 to 15% by weight, more preferably from 1 to 10% by weight, in particular from 2 to 5% by weight, based on the total weight of the tablet.
  • the unambiguous delimitation is therefore preferably based on the fiction that a substance which is used as a specific excipient is not simultaneously used as a further pharmaceutical excipient.
  • mannitol if used as a filler, is not also used as a sweetener.
  • microcrystalline cellulose - if used as a disintegrant - not additionally used as a filler (although microcrystalline cellulose also has filler properties).
  • crospovidone is not also used as a disintegrants (although crospovidone has a strong blast effect).
  • the adjuvants are selected in the melt tablet according to the invention so that the fused tablet according to the invention is free of saccharides.
  • the ingredients described above are processed in the inventive method for orodispersible tablets.
  • the method according to the invention is a "direct compression” (also known as direct compression).
  • the invention therefore provides a process for producing a orodispersible tablet comprising a pharmaceutically acceptable salt of vardenafil, comprising the steps:
  • step (i) of the process according to the invention the components are preferred
  • sweeteners (c) sweeteners; (d) flavoring agents;
  • step (i) of the process according to the invention vardenafil salt (a) and pharmaceutical excipients are mixed.
  • the mixing can be done in conventional mixers.
  • the mixing in positive mixers or gravity mixers can be done, for example by Turbula ® T 1Ob (Bachofen AG, Switzerland).
  • components (a) and (b) are mixed with one another before the implementation of step (i).
  • This premixing takes place, for example, in compulsory mixers or in free-fall mixers.
  • compulsory mixers usually times of 3 to 15 minutes are needed to achieve a homogeneous mixture.
  • free-fall mixers for example by means of Turbula ® T 1OB (Bachofen AG, Switzerland) or container mixers such as CM 500 (J. Engelsmann AG, Germany) or drum mixers such as type Rhönradmischer (J. Engelsmann AG, Germany) are usually times of 10 to 20 Minutes needed to produce the homogeneous mixture.
  • pre-blending components (a) and (b) are usually selected so that at least 10% of the number of vardenafil salt particles used is bound to the mucilage (preferably cohesively), more preferably at least 30% of the Particles, more preferably at least 50% of the particles, in particular at least 90% of the particles.
  • step (ii) the mixture is compressed (from step (i)), i. a compression to tablets.
  • the compression can be done with tableting machines known in the art. The compression takes place in the absence of solvents.
  • Suitable tableting machines are eccentric presses or concentric presses.
  • a Fette 102i (Fette GmbH, Germany) can be used.
  • the mixture of step (i) may be compacted and granulated prior to compression.
  • the granulation is preferably carried out as a dry granulation.
  • a wet granulation can be done.
  • Ingredients (a) to (d) and optionally (e) and (f) and the compression conditions may be selected such that the resulting orodispersible tablet has a drug release in physiological saline greater than 50% to less than 70% at 5.0 minutes , more preferably from 52% to 68%, especially from 55% to 65%.
  • the drug release is determined here in vitro at 37 0 C in 900 ml of physiological saline according to US Pharmacopeia (USP), wherein the measurement is carried out in the Blattrckenerapparatur at 50 revolutions per minute.
  • USP US Pharmacopeia
  • the method according to the invention comprises a further step (iii).
  • the resulting orodispersible tablets are packaged by means of a film which has a water vapor permeability of less than 0.50 g / m 2 d, preferably 0.001 to 0.4 g / m 2 d, more preferably from 0.01 to 0.3 g / m 2 .
  • the parameter "d” hereby means "day.”
  • the packaging is preferably carried out in blister packs, in particular in mono blister packs.
  • the water vapor permeability is determined according to Kassis et al., Pharm. Ind. 43, 1036 (1981).
  • PVC polyvinylidene chloride
  • step (iii) of the method according to the invention is advantageous, in particular for increasing the storage stability of the orodispersible tablets according to the invention.
  • the invention therefore also relates to the use of a film which has a water vapor permeability of less than 0.50 g / m 2 d for packaging a fused tablet containing a medicament for the treatment of erectile dysfunction.
  • the inventive method ensures a technically advantageous manufacturing method. Compared with the wet granulation proposed in the prior art, it is technically less expensive and the space-time yield can be increased. Besides the method according to the invention are also
  • Orodispersible tablets obtainable by the process according to the invention are the subject of this invention.
  • an acrylic polymer or carrageenan is useful for taste masking medicaments for the treatment of erectile dysfunction (which usually have a bitter taste).
  • the invention therefore furthermore relates to the use of an acrylic polymer or of carrageenan for taste masking of orodispersible tablets which contain an active substance for the treatment of erectile dysfunction and are preferably produced by means of direct compression.
  • the tablets according to the invention are advantageously suitable for the treatment of patients with intolerance to sildenafil.
  • intolerance here means that the intake of sildenafil is contraindicated for this patient group for medical reasons.
  • R 4 is -COO-CH 2 -CH 2 -N (CH 3 ) 2 ;
  • Tablets were prepared according to Example 6 of WO 2 006/092207.
  • Tablets prepared according to Examples 1 to 3 were packed in blister packs.
  • the following table shows the different storage stabilities when using different films:
  • Vardenafil salt was added together with all excipients - mixed for 15 minutes in free fall mixer (Turbula ®) - up to Pruv ®. Then Pruv ® was added and mixed for a further 5 minutes. The finished mixture was pressed on a rotary press with biconvex punches (8 mm).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un procédé de fabrication de comprimés à fondre contenant un sel de vardenafil pharmaceutiquement compatible, selon lequel (i) on prépare un mélange contenant du sel de vardenafil pharmaceutiquement compatible, une substance mucilagineuse, un édulcorant, un agent aromatique, et (ii) on comprime directement le mélange pour former un comprimé à fondre. L'invention porte également sur des comprimés obtenus selon ledit procédé.
EP10721683A 2009-05-12 2010-05-10 Comprimé à fondre contenant un sel de vardenafil Withdrawn EP2429528A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009020888A DE102009020888A1 (de) 2009-05-12 2009-05-12 Schmelztablette, enthaltend ein Vardenafil-Salz
PCT/EP2010/002859 WO2010130393A2 (fr) 2009-05-12 2010-05-10 Comprimé à fondre contenant un sel de vardenafil

Publications (1)

Publication Number Publication Date
EP2429528A2 true EP2429528A2 (fr) 2012-03-21

Family

ID=42269437

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10721683A Withdrawn EP2429528A2 (fr) 2009-05-12 2010-05-10 Comprimé à fondre contenant un sel de vardenafil

Country Status (3)

Country Link
EP (1) EP2429528A2 (fr)
DE (1) DE102009020888A1 (fr)
WO (1) WO2010130393A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ303877B6 (cs) 2011-11-24 2013-06-05 Zentiva, K.S. Zpusob prípravy a izolace solí vardenafilu s kyselinami
EP3082428A4 (fr) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Formulations en poudre d'inhibiteur pde5 et procédés y associés
MX2020005890A (es) 2017-12-20 2020-10-19 Klaria Pharma Holding Ab Formulacion de pelicula que comprende vardenafil, metodo para su preparacion y uso de la misma.
IT201900020350A1 (it) * 2019-11-05 2021-05-05 Alpex Pharma Sa Formulazione orodispersibile di vardenafil

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2386420T3 (es) 1997-11-12 2012-08-20 Bayer Pharma Aktiengesellschaft Imidazotriazinonas sustituidas con fenilo en la posición 2 como inhibidores de fosfodiesterasas
KR20000046974A (ko) * 1998-12-31 2000-07-25 윤재승 아세글루타미드 알루미늄의 경구 투여용 제제 조성물ㅇ
EP1817009A2 (fr) * 2004-11-24 2007-08-15 Spi Pharma, Inc. Compositions a desintegration orale
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
MX2008000087A (es) 2005-06-23 2008-03-18 Schering Corp Formulaciones orales rapidamente absorbentes de inhibidores de la fosfodiesterasa 5.
DE102007027067A1 (de) 2007-06-12 2008-12-18 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Vardenafil Hydrochlorid Trihydrat

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2010130393A2 *

Also Published As

Publication number Publication date
WO2010130393A2 (fr) 2010-11-18
WO2010130393A3 (fr) 2011-10-20
DE102009020888A1 (de) 2010-11-18

Similar Documents

Publication Publication Date Title
DE60307082T4 (de) In der mundhöhle dispergierbare phamarzeutische zusammensetzung mit desmopressin
DE3045634C2 (de) Pharmazeutisches Präparat mit langsamer Wirkstofffreisetzung und Verfahren zu dessen Herstellung
DE69802543T2 (de) Verbesserte multipartikel-tablette mit schnellauflösbarkeit
DE69610323T2 (de) Sich schnell im munde auflösende zusammensetzungen für dopaminagonisten
DE60220408T2 (de) Sequenzielles arzneimittelabgabesystem
EP1858490B1 (fr) Formes pharmaceutiques a proprietes pharmacocinetiques ameliorees
US20110142931A1 (en) Soft tablet containing dextrose monohydrate
EP2334284B1 (fr) Cinacalcet compacté
WO2006002836A1 (fr) Compositions effervescentes de somniferes
EP2413910A1 (fr) Comprimés contenant de la dapoxétine et procédé de traitement à sec pour leur préparation
WO2011072839A1 (fr) Comprimé orodispersible contenant de la dapoxétine
EP2429528A2 (fr) Comprimé à fondre contenant un sel de vardenafil
WO2010105822A2 (fr) Transformation à sec de rétigabine
EP2515852B1 (fr) Comprimé orodispersible contenant une base de sildenafil compactée
KR20150002453A (ko) 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
AU2003240164A1 (en) Extended release formulation of divalproex sodium
WO2010105824A1 (fr) Comprimés de rétigabine, de préférence à libération modifiée
EP2938328A1 (fr) Forme galénique monolithique pour la libération modifiée d'une combinaison de principes actifs
EP2416755B1 (fr) Comprime orodispersible contenant un sel de sildenafil
DE10338544A1 (de) Buccale Formulierungen des Galanthamins und deren Anwendungen
EP3299010B1 (fr) Forme pharmaceutique orale
EP2566452A1 (fr) Comprimé soluble comprenant un triptane ou un neuroleptique atypique
EP3758675A1 (fr) Forme pharmaceutique orale contenant du cacao sans théobromine
DE102012113098A1 (de) Monolithische Arzneiform zur modifizierten Freisetzung einer Wirkstoffkombination

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20111114

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20121015

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: RATIOPHARM GMBH

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/53 20060101ALI20161014BHEP

Ipc: A61K 9/20 20060101AFI20161014BHEP

INTG Intention to grant announced

Effective date: 20161109

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170321